OTCMKTS:HKMPY Hikma Pharmaceuticals (HKMPY) Stock Price, News & Analysis → Dividend-like income from non-dividend stocks (From Unstoppable Prosperity) (Ad) Free HKMPY Stock Alerts $49.79 0.00 (0.00%) (As of 05/22/2024 ET) Add Compare Share Share Today's Range$49.79▼$49.7950-Day Range$46.16▼$51.5552-Week Range$42.23▼$56.63Volume77 shsAverage Volume937 shsMarket CapitalizationN/AP/E Ratio16.08Dividend Yield0.64%Price TargetN/A Stock AnalysisStock AnalysisChartDividendHeadlinesShort InterestStock AnalysisChartDividendHeadlinesShort Interest Get Hikma Pharmaceuticals alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPY)Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.Read More HKMPY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HKMPY Stock News HeadlinesApril 15, 2024 | finance.yahoo.comWith 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big gunsFebruary 22, 2024 | msn.comHikma shares spike after pharma giant’s profit up 30 per centFebruary 21, 2024 | prnewswire.comHikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facilityFebruary 5, 2024 | finanznachrichten.deHikma Pharmaceuticals USA Inc.: Hikma announces US launch of COMBOGESIC IVFebruary 5, 2024 | markets.businessinsider.comHikma Pharma Launches Pain Relief Injection COMBOGESIC IV In USFebruary 5, 2024 | finance.yahoo.comHikma announces US launch of COMBOGESIC® IVJanuary 22, 2024 | finance.yahoo.comActiv Surgical Announces Completion of First International Procedure Using Its ActivSight™ Intelligent LightJanuary 8, 2024 | finance.yahoo.comGuardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North AfricaNovember 6, 2023 | finance.yahoo.comHikma Pharmaceuticals PLC's (LON:HIK) institutional investors lost 5.8% over the past week but have profited from longer-term gainsAugust 17, 2023 | msn.comSK Biopharm inks license deal with Hikma's Middle East unitAugust 15, 2023 | marketwatch.comHikma Pharmaceuticals outperforms market despite losses on the dayAugust 8, 2023 | msn.comHikma Pharmaceuticals goes ex dividend tomorrowAugust 6, 2023 | finance.yahoo.comIs It Worth Considering Hikma Pharmaceuticals PLC (LON:HIK) For Its Upcoming Dividend?June 27, 2023 | thestreet.comHikma Trims Full-Year Revenue Guidance After Advair Diskus DelayJune 15, 2023 | finance.yahoo.comHikma exceeds 150 injectable medicines in the US with launch of Dobutamine Injection, USPMay 31, 2023 | uk.finance.yahoo.comFTSE 100: Ocado at risk, IMI in – how London Stock Exchange is set to reshuffle the indexMay 5, 2023 | marketwatch.comHikma Pharmaceuticals rises Friday, still underperforms marketMay 3, 2023 | marketwatch.comHikma Pharmaceuticals rises Wednesday, outperforms marketMarch 19, 2023 | finance.yahoo.comHikma Pharmaceuticals Full Year 2022 Earnings: EPS Misses ExpectationsFebruary 7, 2023 | uk.investing.comHikma Pharmaceuticals PLC (HIK)January 31, 2023 | marketwatch.comHikma Pharmaceuticals rises Tuesday, outperforms marketJanuary 24, 2023 | marketwatch.comHikma Pharmaceuticals falls Tuesday, underperforms marketDecember 27, 2022 | msn.comJunshi inks licensing deal with Hikma for toripalimab; FDA filing still under reviewDecember 26, 2022 | financialpost.comJunshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa RegionDecember 15, 2022 | marketwatch.comHikma Pharmaceuticals rises Thursday, outperforms marketSee More Headlines Receive HKMPY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 5/13 Dividend3/21/2024Dividend Payable5/13/2024Today5/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:HKMPY CUSIPN/A CIKN/A Webwww.hikma.com Phone442073992760FaxN/AEmployees9,100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio16.08 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesEngineer Said Samih Taleb Darwazah (Age 67)Executive Chairman Comp: $2.8MMr. Riad Ali Mishlawi (Age 60)CEO & Director Comp: $1.1MMr. Mazen Samih Taleb Darwazah (Age 66)Executive Vice Chairman & President of MENA Comp: $2.3MMr. Khalid Waleed Hosny Al Nabilsi (Age 52)Chief Financial Officer Patricia BousfieldChief Information OfficerMr. Guy FeatherstoneAssociate Director of Investor RelationsMr. Samuel ParkGeneral CounselMr. Bassam Wael Rushdi Kanaan CFA (Age 59)CPA, Executive Vice President of Corporate Development and M&A Mr. Hussein Omar ArkhaghaChief People OfficerMs. Susan RingdalExecutive Vice President of Strategic Planning & Global AffairsMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors HKMPY Stock Analysis - Frequently Asked Questions How have HKMPY shares performed in 2024? Hikma Pharmaceuticals' stock was trading at $45.4110 at the beginning of the year. Since then, HKMPY shares have increased by 9.6% and is now trading at $49.79. View the best growth stocks for 2024 here. How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals declared a dividend on Wednesday, March 6th. Stockholders of record on Friday, March 22nd will be given a dividend of $0.92 per share on Monday, May 13th. The ex-dividend date of this dividend is Thursday, March 21st. This is an increase from the stock's previous dividend of $0.48. Read our dividend analysis for HKMPY. Is Hikma Pharmaceuticals a good dividend stock? Hikma Pharmaceuticals (OTCMKTS:HKMPY) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.65%. The dividend payout ratio is 10.34%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for HKMPY. How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:HKMPY) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersDividend-like income from non-dividend stocksUnstoppable ProsperityTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThe most important AI company you've never heard ofManward PressBill Gates is all about this tiny $2 stockTimothy SykesTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaElon to Transform U.S. Economy? Porter & CompanyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.